menu
    • menu
    [{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sankyo \/ Merck & Co"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Daiichi Sankyo

                            Japan arrow
                            EPS
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raludotatug Deruxtecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2/3 of Raludotatug Deruxtecan Begins in Platinum-Resistant Ovarian Cancer Patients

                            Details : R-DXd (raludotatug deruxtecan) potential first-in-class CDH6 directed DXd antibody drug conjugate. It is being evaluated for the treatment of patients with platinum-resistant ovarian cancer.

                            Product Name : DS-6000a

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            March 04, 2024

                            Lead Product(s) : Raludotatug Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ono Pharmaceutical

                            Japan arrow
                            EPS
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONO Submits Supplemental Application for Approval for Opdivo® to Expand the Use in Recurrent Gastric Cancer

                            Details : The supplemental application for approval for Opdivo® has been filed based on the data from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44) and ATTRACTION-4 study (ONO-4538-37.

                            Product Name : Opdivo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 12, 2020

                            Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth